On Monday, Sage Therapeutics Inc (NASDAQ: SAGE) opened higher 3.89% from the last session, before settling in for the closing price of $7.72. Price fluctuations for SAGE have ranged from $4.62 to $20.76 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3403.60% over the past five years. Company’s average yearly earnings per share was noted 46.51% at the time writing. With a float of $54.13 million, this company’s outstanding shares have now reached $61.36 million.
Let’s look at the performance matrix of the company that is accounted for 353 employees. In terms of profitability, gross margin is 77.1%, operating margin of -1046.9%, and the pretax margin is -971.48%.
Sage Therapeutics Inc (SAGE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sage Therapeutics Inc is 11.95%, while institutional ownership is 74.84%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.39% during the next five years compared to 13.20% growth over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Check out the current performance indicators for Sage Therapeutics Inc (SAGE). In the past quarter, the stock posted a quick ratio of 7.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.60, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -2.65 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (NASDAQ: SAGE) saw its 5-day average volume 1.38 million, a negative change from its year-to-date volume of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 82.99%. Additionally, its Average True Range was 0.32.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 83.33%, which indicates a significant decrease from 83.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.48% in the past 14 days, which was lower than the 83.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.14, while its 200-day Moving Average is $7.88. Nevertheless, the first resistance level for the watch stands at $8.26 in the near term. At $8.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.78. If the price goes on to break the first support level at $7.74, it is likely to go to the next support level at $7.46. The third support level lies at $7.22 if the price breaches the second support level.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
There are currently 61,481K shares outstanding in the company with a market cap of 493.07 million. Presently, the company’s annual sales total 41,240 K according to its annual income of -400,670 K. Last quarter, the company’s sales amounted to 12,820 K and its income totaled -95,780 K.
